1.         GWD-23-Q10

When trying to identify new technologies that promise to transform the marketplace, market researchers survey the managers of those companies that are developing new technologies. Such managers have an enormous stake in succeeding, so they invariably overstate the potential of their new technologies. Surprisingly, however, market researchers typically do not survey a new technology’s potential buyers, even though it is the buyers-not the producers-who will ultimately determine a technology’s commercial success.

Which of the following, if true, best accounts for the typical survey practices among market researchers?

1. If a new technology succeeds, the commercial benefits accrue largely to the producers, not to the buyers, of that technology.

2. People who promote the virtues of a new technology typically fail to consider that the old technology that is currently in use continues to be improved, often substantially.

3. Investors are unlikely to invest substantial amounts of capital in a company whose own managers are skeptical about the commercial prospects of a new technology they are developing.

4. The potential buyers for not-yet-available technologies can seldom be reliably identified.

5. The developers of a new technology are generally no better positioned than its potential buyers to gauge how rapidly the new technology can be efficiently mass-produced.

请问这是什么题型 题目没看明白

请NN讲下这个题

1.         GWD-23-Q1

A major health insurance company in Lagolia pays for special procedures prescribed by physicians only if the procedure is first approved as “medically necessary” by a company-appointed review panel.  The rule is intended to save the company the money it might otherwise spend on medically unnecessary procedures.  The company has recently announced that in order to reduce its costs, it will abandon this rule.

Which of the following, if true, provides the strongest justification for the company’s decision?

A.      Patients often register dissatisfaction with physicians who prescribe nothing for their ailments.

B.       Physicians often prescribe special procedures that are helpful but not altogether necessary for the health of the patient.

C.       The review process is expensive and practically always results in approval of the prescribed procedure.

D.      The company’s review process does not interfere with the prerogative of physicians, in cases where more than one effective procedure is available, to select the one they personally prefer.

E.       The number of members of the company-appointed review panel who review a given procedure depends on the cost of the procedure.

这道我选C，答案是C，可是B为什么错？？？

这道我选C，答案是C，可是B为什么错？？？

GWD-23-Q10

best accounts for :

D. The potential buyers for not-yet-available technologies can seldom be reliably identified.

我怎么觉得像conclude啊，因为这个正确选项和researcher的观点是重合的，似乎没有什么GAP

GWD-23-Q1

我认为B不是无关的，只是没有C那么strong（题目问strongest justification)：

B是说，医生在review的时候经常开一些不必要的药（安利纽崔莱、脑白金之类的)，言外之意增加公司的额外医疗费用，因此需要取消这个方案

不知道这样理解对不对

Q10 类型 Paradox
题目提出的是一个矛盾:

 1. 在衡量新技术的市场潜力时,研发经理的态度是有偏向的.(这个我深有体会..呵呵..)

2. 但是市场通常不调查新技术的最终用户(而是调查研发经理).尽管最终用户的影响决定该技术的前景.
Paradox的正确选项要能解释矛盾的双方面,即1,2要同时成立.
D:指出新技术的最终用户是很难identify的.1,2同时成立.

23-Q1
B不是无关,而是WEAKEN.B的存在使得对治疗手段的REVIEW存在效果,而不能被取消.

Q10 类型 Paradox
题目提出的是一个矛盾: 1. 在衡量新技术的市场潜力时,研发经理的态度是有偏向的.(这个我深有体会..呵呵..)
                                          2. 但是市场通常不调查新技术的最终用户(而是调查研发经理).尽管最终用户的影响决定该技术的前景.
Paradox的正确选项要能解释矛盾的双方面,即1,2要同时成立.
D:指出新技术的最终用户是很难identify的.1,2同时成立.

D有让1,2都成立吗？好象没有，只使2成立了，不过只要充分即可，所以对

LS看原文最后一句, 最终的成功是有buyer决定的, 就是说, 有没有利润, buyer说了算, 和制造商没关系

这也正是题目问为什么不去调查buyer, 却去调查制造商的原因, 因为是一个需要解决的矛盾

在说简单点就是, 这个东西成功不成功, 为什么不问决定权buyer, 却去问没有决定权制造商

A 选项说利润是制造商的, 不能解决这么矛盾, 且利润归属于题目无关, 不是答案